VECURONIUM BROMIDE FOR INJECTION

Vecuronium Bromide for Injection is a freeze-dried powder containing 10 mg of the active ingredient, supplied in a package of ten vials, with a total shelf life of twenty-four months. At the time of receipt by the first government activity, the product must have a minimum of twenty-one months of remaining shelf life and must be stored under controlled room temperature conditions between 20 to 25ºC (68 to 77ºF), protected from light. Packaging must comply with commercial standards as specified in the procurement document, including sealed unit containers to prevent damage and suitable exterior shipping containers ensuring safe delivery at the lowest rate to the destination. All labeling and marking must adhere to Medical Marking Standard No. 1, which supersedes MIL-STD-129, and packaging must follow DLA’s Technical and Quality Requirements as outlined in the DLA Master List. The item is not classified as hazardous under Fed-Std-313 and must be commercially packaged in accordance with ASTM D3951 unless overridden by higher-priority DLA requirements. The product is manufactured by Hikma Pharmaceuticals USA Inc. under NDC 00143-9234-10 and is identified by NSN 6505-01-258-0983. The contract requires delivery of one package within twenty days to the destination at Nellis Air Force Base, Nevada, with no variance allowed in quantity. Delivery must occur via traceable freight methods, not parcel post, and is governed by the solicitation number SPE2DP-26-T-4487 with a required delivery date of August 6, 2026. The unit of issue is a package, and the entire order is priced as a single unit. All technical, quality, and packaging provisions take precedence over general standards, and the item is subject to government inspection and acceptance at the point of delivery.